The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
A Phase IB Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 331813405
- South Florida Bioavailability Clinic
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- The CORE Ctr
-
Chicago, Illinois, United States, 60610
- Chicago Ctr for Clinical Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Anderson Clinical Research
-
Pittsburgh, Pennsylvania, United States, 15221
- Anderson Clinical Research
-
-
South Carolina
-
Columbia, South Carolina, United States, 29206
- Burnside Clinic
-
-
Texas
-
Galveston, Texas, United States, 775550835
- Univ of Texas Med Branch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Are at least 18 years old.
- Agree to use effective methods of birth control during the study.
- Have a CD4 cell count of 200 cells/mm3 or more.
- Have HIV levels of 5000 copies/ml or more.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have abnormal blood tests.
- Have had a reaction to study medication.
- Have a history of opportunistic (AIDS-related) infection or cancer.
- Are being treated for active pulmonary tuberculosis.
- Have a fever of 39 degrees C or more within 14 days of beginning study treatment.
- Are unable to take medications by mouth.
- Have an abnormal chest X-ray or ECG within 30 days of beginning study treatment.
- Have hepatitis, hemophilia, or other blood disorder.
- Have significant heart, stomach, intestinal, liver, nerve, or kidney problems.
- Have a condition which may affect ability to participate in this study, such as drug or alcohol abuse or a serious mental disorder.
- Have taken anti-HIV drugs in the past.
- Are taking certain medications.
- Have had a blood transfusion within the 3 months prior to entering the study.
- Have had radiation or chemotherapy within 16 days before the screening visit or plan to receive such treatment during the study.
- Are pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Calanolide A
Other Study ID Numbers
Other Study ID Numbers
- 297B
- 57CL-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.